米氮平与阿米替林治疗抑郁症对照研究

A controlled study of mirtazapine and amitrptyline in depression

目的 评价米氮平治疗抑郁症的临床疗效、不良反应及其安全性。方法将 4 0例符合CCMD 2 R抑郁症诊断标准的患者随机分为研究组 (米氮平治疗组 ) 2 0例 ,对照组 (阿米替林治疗组 ) 2 0例 ,采用HAMD量表在治疗前及治疗第 1、2、4、6w末评定药物疗效 ,TESS量表评定不良反应。结果 米氮平治疗抑郁症有率为 90 % ,与阿米替林 (95 % )相当 (P >0 .0 5 ) ;不良反应 :研究组为体重增加 (2 0 % )、嗜睡 (10 % )、头痛 (10 % )、下肢水肿 (0 .5 % ) ,对照组为口干 (6 0 % )、便秘 (35 % )、视物模糊 (30 % )、心动过速(2 0 % )、心电图改变 (0 .5 % )。米氮平的不良反应明显少于阿米替林组 ,两组间比较有显著性差异 (P <0 .0 5 )。结论 米氮平与阿米替林的抗抑郁疗效相当 ,而不良反应米氮平比阿米替林少。提示 ,米氮平是一种安全有效的新一代抗抑郁药。

Objective To evaluate the curative effects ,adverse reactions and safety of mirtazapine in the treatment of depression. Methods 20 patients with depression were randomly assigned to research (n=20,took mirtazapine) and controlled groups(n=20,amitriptyline ).Curative effects were evaluated with the HAMD before treatment and at the ends of 1^(st) , 2^(nd) , 4^(th) and 6^(th) weeks of treatment and adverse reactions with the TESS. Results The effective rates of mirtazapine and amitrptyline were 90% and 95% respectively and that had no significant difference(P>0.05) ,and the adverse reactions of the former were significantly fewer than those of the latter. Conclusion Curative effect of mirtazapine is correspond to amitriptyline and the adverse reactions are fewer. Mirtazapine is a safe and effective neo-antidepressant.